About Us

Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for GraliseCambiaZipsor, and Lazanda.

In addition to its ability to develop and commercialize new drugs, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

Going forward, the company’s strategy is to continue to identify, license and develop new products that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue.

Key Facts

Headquarters: Newark, CA

Nasdaq symbol: DEPO

Number of employees: Approx. 325

Marketed Products:

Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN)

Cambia® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory (NSAID) drug for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients

Addressing Important Markets

Postherpetic Neuralgia

Mild to Moderate Acute Pain

Breakthrough Pain in Cancer Patients

Migraine

Products Marketed By Partners

Glumetza® (metformin hydrochloride extended-release tablets) by Santarus

Janumet® XR (sitagliptin/metformin HCl extended-release) tablets by Merck

Nucynta® ER (tapentadol) extended-release oral tablets by Janssen